TRDA Stock — Entrada Therapeutics Inc.: Cash, EV, Pipeline

Share price

$6.75

Market cap

$262.8M

Cash

$99.3M

Enterprise value

$163.5M

Balance sheet

Cash	$99.3M
Debt	$0.0M
Net cash	$99.3M
Enterprise value	$163.5M
Basic shares	38.9M shares
Fully diluted shares	48.0M shares
Fully diluted market cap	$323.9M
Cash per share	$2.55

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TRDA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24	ENTR-601-45	Phase 2	Duchenne Muscular Dystrophy (DMD)	—
May 9 - Jun 20	ENTR-601-44	Phase 2	Duchenne Muscular Dystrophy (DMD)	—
Apr 12 - May 24	ENTR-601-44	Phase 2	Duchenne Muscular Dystrophy (DMD)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ENTR-601-44

Phase 1 · Active Modality: EEV-conjugated PMO (endosomal escape vehicle)

Target DMD

Indications

Duchenne muscular dystrophy (exon 44 amenable) (Phase 1)

Catalysts

— End 2026
— Q1 2027

Status note Global Phase 1/2 ELEVATE-44-201: Cohort 1 (6 mg/kg) completed; Cohort 2 (12 mg/kg) fully enrolled; Cohort 3 (up to 18 mg/kg) to follow if needed; expansion cohort planned to support potential US accelerated approval. FDA Rare Pediatric Disease Designation.

ENTR-601-45

Phase 1 · Active Modality: EEV-conjugated PMO (endosomal escape vehicle)

Target DMD

Indications

Duchenne muscular dystrophy (exon 45 amenable) (Phase 1)

Catalysts

— October 2026
— H1 2027

Status note Global Phase 1/2 ELEVATE-45-201: Cohort 1 dosing complete; Cohort 2 dosing ongoing.

VX-670

Phase 1 · Active Modality: EEV-based genetic medicine

Target CUG repeats

Partnerships Vertex: global research collaboration; Vertex running GALILEO Phase 1/2 clinical trial

Indications

Myotonic dystrophy type 1 (Phase 1)

Catalysts

— H2 2026

Status note GALILEO global Phase 1/2 completed enrollment and continues dosing in MAD portion; assessing safety, splicing index, and muscle function/strength.

ENTR-601-50

Stage not disclosed · Active Modality: EEV-conjugated PMO (endosomal escape vehicle)

Target DMD

Indications

Duchenne muscular dystrophy (exon 50 amenable) (Stage not disclosed)

Status note Regulatory applications to be submitted following review of data from lead programs; timeline guidance pending.

ENTR-601-51

Preclinical · Active Modality: EEV-conjugated PMO (endosomal escape vehicle)

Target DMD

Indications

Duchenne muscular dystrophy (exon 51 amenable) (Stage not disclosed)

Status note IND-enabling studies completed; regulatory application not yet filed.

ENTR-801

Preclinical · Active Modality: oligonucleotide

Target USH2A

Indications

Usher syndrome type 2A (exon 13 amenable) (Preclinical)

Status note First ocular clinical candidate (announced December 2025), designed to restore functional usherin protein. Second ocular candidate expected to be announced H2 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ENTR-601-45
Lead indication	Duchenne Muscular Dystrophy (DMD)
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07038824	Phase 2	Recruiting	Sponsor	TRDA	—	Duchenne Muscular Dystrophy (DMD)	—
NCT07037862	Phase 2	Recruiting	Sponsor	TRDA	—	Duchenne Muscular Dystrophy (DMD)	—
NCT07682129	Phase 2	Not yet recruiting	Sponsor	TRDA	—	Duchenne Muscular Dystrophy (DMD)	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Entrada Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	5,072,730	no change	0.19%	2026-08-14
ADAR1 Capital Management	15,500	-15,000	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

TRDA — Entrada Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders